Erleada patent expiration?

Short answer:

• United States: The core patent protecting apalutamide (Erleada’s active ingredient) expired in 2020.
  • A few secondary, formulation‑ and method‑of‑use patents still cover the product until 2025.
• European Union: The main patent expires in 2023.
• Canada: Patents run out in 2024.
• Generic availability: Generic versions are expected to enter the market only after all relevant patents have lapsed – roughly 2025–2026 in the U.S., 2023–2024 in the EU/Canada.

Why the dates differ

1. Core vs. secondary patents

   • Core patents cover the chemical structure of apalutamide itself. These were the first patents filed (e.g., US 8,210,154) and ran to 2020.
   • Secondary patents cover novel salts, crystalline forms, manufacturing processes, and specific dosage‑form compositions. These are often granted 10–12 years after the core patent and can extend exclusivity for several more years.

2. Jurisdictional differences

   • Patents are filed and granted by country. A U.S. patent expiry does not automatically apply in Europe or Canada, so each region has its own set of dates.

3. Patent litigation

   • Pfizer has fought against early generic filings. While the core patents are expired, some secondary patents and litigation hold-ups can delay generic entry.

What this means for patients and payers

• Price: Once the core patents lapse, generic manufacturers can start producing apalutamide, which typically drives down cost.
• Supply: In the U.S., generics are still a few years away; in the EU and Canada, generic competition may begin in 2023–2024.
• Insurance coverage: Payers may adjust coverage policies to favor generics once they’re available, potentially improving affordability.

Key take‑away

• US core patents expired in 2020 → generic manufacturing can start but is subject to secondary patents and regulatory clearance.
• Generic entry expected around 2025–2026 in the U.S.
• Earlier entry in the EU (2023) and Canada (2024) as their patents expire.

Feel free to let me know if you need details on specific patent numbers or the status of FDA generic applications!